stockrowZoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.
- Revenue
- −0.24%
- EPS
- +2.48%
- Free cash flow
- +17.4%
- Total debt
- +37.5%
Quarter to June 2026, against a year earlier
Follow ZTS
Alert me
Zoetis Inc. (ZTS) Free cash flow
Zoetis Inc.'s free cash flow for fiscal 2025 was $2.3B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $2.3B. Over the past ten years it has ranged from $442.0M (fiscal 2015) to $2.3B (fiscal 2024); the current reading is higher than 91% of that period. Zoetis Inc. ranks 4th of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $2.3B | (0.65%) |
| FY2024 | $2.3B | 41.76% |
| FY2023 | $1.6B | 22.16% |
| FY2022 | $1.3B | (23.65%) |
| FY2021 | $1.7B | 2.60% |
| FY2020 | $1.7B | 24.93% |
| FY2019 | $1.4B | (10.08%) |
| FY2018 | $1.5B | 30.11% |
| FY2017 | $1.2B | 97.44% |
| FY2016 | $587.0M | 32.81% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $539.0M | 79.07% |
| Mar 2026 | $301.0M | (58.82%) |
| Dec 2025 | $731.0M | (3.31%) |
| Sep 2025 | $756.0M | 64.71% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $8.0B |
| HLN Haleon PLC Sponsored ADR compare | $4.6B |
| VTRS Viatris Inc. compare | $2.4B |
| ZTS Zoetis Inc. | $2.3B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.3B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.0B |
| UTHR United Therapeutics Corporation compare | $867.2M |
| ELAN Elanco Animal Health Incorporated compare | $379.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $96.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement